Sarah received her Ph.D. in Chemical and Systems Biology at Stanford. Her unique background encompasses multiple areas of drug development, from preclinical oncology research at Pfizer to drug repurposing at Stanford’s School of Medicine. Her breadth of experience enables her to provide her clients with incisive drug landscape analyses and key insights.